CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 50 enrolled
Drug / intervention
Buprenorphine/naloxone +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01550341
NCT01550341N/ACompleted
CompareCT.gov

HIV, Buprenorphine, and the Criminal Justice System

Yale University·interventional·Posted Mar 12, 2012·Updated May 6, 2020

In Brief

A clinical study evaluating Buprenorphine/naloxone and Placebo Oral Tablet for Human Immunodeficiency Virus and 3 related conditions. Completed, enrolled 50 participants across 1 site.

Detailed Summary

The aims of STRIDE were changed as of July, 2014. The revised project, called STRIDE2, has a longitudinal, non-randomized, observational study design. The population under study consists of individuals living with HIV who are dependent on opioids.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuman Immunodeficiency Virus, Acquired Immunodeficiency Syndrome, Opiate Addiction, Drug Dependence
CountriesUnited States
CollaboratorsGeorge Mason University, Howard University, National Institute on Drug Abuse (NIDA)

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 12, 2012
Enrollment StartFeb 23, 2012
Primary CompletionNov 30, 2015
Study CompletionNov 30, 2016
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 14.3 years ago

Interventions

Buprenorphine/naloxonedrug

2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.

Placebo Oral Tabletdrug

2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.